Repligen (RGEN) Peer Comparison
$180.71
$3.82
(2.16%)
As on 21-Sep-2026 16:00EDT
Market cap
$9,983 Mln
Revenue (TTM)
$785 Mln
P/E Ratio
242.3
P/B Ratio
4.8
Div. Yield
0 %
Edit
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
9,983 | 12,560 | 10,497 | 9,521 | 9,770 |
Revenue ($ Mln) |
785 | 1,505 | 6,561 | 613 | 2,589 |
Net Profit ($ Mln) |
41.54 | 160.59 | -578.00 | -188.05 | 222.40 |
Net Margin (%) |
5.29 | 10.67 | -8.81 | -30.68 | 8.59 |
RoE (%) |
1.97 | 10.86 | -10.33 | -28.10 | 3.04 |
Price to Earnings |
242.32 | 78.15 | -- | -- | 44.47 |
Price-To-Book |
4.76 | 8.19 | 1.91 | 14.13 | 1.36 |
Income Statement ($ Mln)
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
785.10 | 1,504.87 | 6,561.10 | 612.84 | 2,589.30 |
|
Cost of Revenue
|
384.30 | 483.98 | 4,473.00 | 127.96 | 1,245.50 |
|
Gross Profit
|
347.62 | 942.44 | 2,139.40 | 393.22 | 1,343.60 |
|
Operating Expenses
|
335.50 | 833.56 | 2,373.70 | 565.37 | 1,108.90 |
|
Operating Profit (EBIT)
|
65.30 | 187.34 | -285.60 | -80.49 | 235.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
52.15 | 203.83 | -472.00 | -192.83 | 350.40 |
|
Provision for Tax
|
10.61 | 43.24 | 106.00 | -4.79 | 128.00 |
|
Profit after Tax (Net Income)
|
41.54 | 160.59 | -578.00 | -188.05 | 222.40 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 93.19 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,112.03 | 1,530.77 | 5,630.20 | 682.49 | 7,173.90 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
705.49 | 210.18 | 4,583.70 | 135.71 | 2,116.80 |
|
Current Liabilities
|
132.66 | 233.78 | 1,382.00 | 102.33 | 961.30 |
|
Total Liabilities
|
2,949.70 | 1,826.52 | 11,794.70 | 893.49 | 10,576.50 |
Assets ($ Mln)
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,749.63 | 630.60 | 9,133.70 | 404.74 | 7,231.50 |
|
Current Assets
|
1,200.55 | 1,344.12 | 2,462.20 | 515.78 | 3,020.50 |
|
Total Assets
|
2,949.70 | 1,826.52 | 11,794.70 | 893.49 | 10,576.50 |
|
Total Debt*
|
690.94 | 212.71 | 3,697.80 | 102.84 | 1,203.70 |
|
Net Current Assets
|
1,067.90 | 1,110.35 | 1,080.20 | 413.45 | 2,059.20 |
Cashflow ($ Mln)
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
117.42 | 238.66 | 623.80 | -46.34 | 532.20 |
|
Cash Flow from Investing Activities
|
-298.47 | -404.59 | -130.50 | -77.61 | -189.70 |
|
Cash from Financing Activities
|
-15.21 | 26.53 | -409.40 | 11.89 | -283.20 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
1.79 | 11.76 | -5.43 | -22.53 | 8.98 |
|
ROE (%)
|
1.97 | 10.86 | -10.33 | -28.10 | 3.04 |
|
ROA (%)
|
1.36 | 7.95 | -4.08 | -18.00 | 2.02 |
|
EBIT Margin (%)
|
9.87 | 13.63 | -4.47 | -30.58 | -5.99 |
|
Net Margin (%)
|
5.29 | 10.67 | -8.81 | -30.68 | 8.59 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
16.49 | 17.55 | -1.57 | 41.55 | 1.37 |
|
EBIT Growth (%)
|
920.91 | 17.49 | -129.16 | -116.42 | -131.06 |
|
Net Profit Growth (%)
|
400.42 | 8.72 | -184.08 | -102.66 | -30.32 |
|
EPS Growth (%)
|
394.30 | 8.12 | -184.11 | -96.88 | -29.66 |
|
Book Value Growth (%)
|
2.16 | 17.33 | -9.82 | -12.65 | 2.19 |
Valuation Ratios
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
189.42 | 68.93 | -14.68 | -34.59 | -- |
|
Price / Book Value
|
4.40 | 8.58 | 1.40 | 9.90 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
55.90 | 53.25 | 81.94 | -43.50 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.26 | 0.00 | 0.65 | 0.00 | 0.11 |
|
Short term debt to equity ratio
|
0.01 | 0.01 | 0.01 | 0.00 | 0.06 |
|
Current Ratio
|
9.05 | 5.75 | 1.78 | 5.04 | 3.14 |
|
Quick Ratio
|
7.64 | 3.86 | 1.18 | 4.46 | 2.33 |
|
Interest Coverage
|
1.92 | 157.91 | -1.64 | -38.31 | 8.18 |
Operating Efficiency Ratios
| Repligen (RGEN) | Penumbra (PEN) | Avantor (AVTR) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
20.09 | 12.65 | 17.36 | 22.67 | 17.06 |
|
Asset Turnover
|
0.26 | 0.74 | 0.46 | 0.59 | 0.24 |
|
Receivable days
|
72.41 | 46.54 | 58.79 | 60.95 | 65.39 |
|
Inventory Days
|
146.53 | 331.92 | 64.13 | 193.84 | 221.09 |
|
Payable days
|
29.05 | 26.16 | 58.13 | 60.19 | 37.02 |
|
Cash Conversion Cycle
|
189.88 | 352.30 | 64.79 | 194.60 | 249.46 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
